Home / Evidence ledger / TB-500
7 amino acids · fragment of thymosin β4
Under reviewA seven-amino-acid fragment of a naturally occurring protein. Not the protein itself, which is a distinction most marketing ignores. Preclinical only. Advisory panel voted favourably in July 2026; no final rule has been issued.
Free, no obligation
Every inquiry gets a real answer from a person. If what you're asking about isn't supported by evidence, we'll say so.
Schematic structure, not to scale. Beads represent amino acid residues along the backbone.
In theory, TB-500 is designed to mobilise cells into damaged tissue. Binding actin to promote cell migration and new blood vessel formation, which is the basis for every claim about connective tissue recovery and flexibility. The parent protein it is drawn from, thymosin beta-4, is a genuine regulator of tissue repair with real clinical trial history. Whether a seven-amino-acid fragment reproduces that in people has not been tested.
The detail, if you want it
Thymosin beta-4 is a real 43-amino-acid protein found throughout human tissue. TB-500 is not that protein. It is a short synthetic fragment, usually the sequence LKKTETQ, drawn from the actin-binding region. This matters because trial data that exists for thymosin beta-4 itself does not automatically apply to the fragment being sold.
The fragment binds actin and is thought to promote cell migration and new blood vessel formation, which is the basis for the tissue repair claims. The mechanism is reasonably characterised in cell and preclinical models.
That is the question a consultation answers. A licensed physician reviews your situation and tells you what the evidence supports. Including when the honest answer is no.
See consultationsAlso on the ledger